The biopharma industry will see seven blockbuster launches this year, according to Clarivate’s annual “Drugs to Watch” list for 2019! See how they rank: AbbVie’s upadacitinib […]
Insys Therapeutics settled with the feds for $225M on federal kickback charges, but things continue to escalate for the opioid maker. Insys filed for Chapter […]
A trio of Kendall Square buildings that are home to big-name drug companies traded hands for one of the steepest prices ever seen in Boston’s office […]
AbbVie will acquire Allergan in a $63B deal, answering questions over the company’s future beyond its top-selling drug Humira. Combined, the companies would rank as one […]
Since its U.S. approval in 2004, Pfizer’s Lyrica has topped the company’s pharma sales charts, but now its patent cliff is here. The FDA approved copycats […]